Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress

The proteasome inhibitor bortezomib has proven to be invaluable in the treatment of myeloma. By exploiting the inherent high immunoglobulin protein production of malignant plasma cells, bortezomib induces endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), resulting in myeloma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Wallington-Beddoe, Craig T., Bennett, Melissa K., Vandyke, Kate, Davies, Lorena, Zebol, Julia R., Moretti, Paul A.B., Pitman, Melissa R., Hewett, Duncan R., Zannettino, Andrew C.W., Pitson, Stuart M
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Priority Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546428/
https://ncbi.nlm.nih.gov/pubmed/28467788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17115
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados